FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Fosamax | Merck

SPOTLIGHT: Doubt cast on Fosamax link to jaw decay

Tools

A new study by a Harvard dental professor may cast doubt on some claims that Merck's osteoporosis drug Fosamax caused some patients' jawbones to decay. The study shows that IV forms of the drug may have contributed to jaw disorders, but oral forms--which are far more commonly prescribed--actually reduced that risk. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Merck   Fosamax